The company's proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative and liver conditions. Axcella's product candidates are comprised of multiple endogenous metabolic modulators (EMMs) that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. The company's pipeline includes lead therapeutic candidates for the reduction in risk of recurrent overt hepatic encephalopathy, non-alcoholic steatohepatitis, and Long COVID. Axcella's unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials.